Immune thrombocytopenic purpura: A rare side effect in a patient treated with Imiquimod for lentigo maligna
Topical Imiquimod is increasingly used in the treatment of lentigo maligna (LM) for patients not suitable or willing for surgery. It acts as an immune response modifier and is recommended for use with caution in patients with autoimmune disorders. A review of the literature did not reveal any report...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-09-01
|
| Series: | JPRAS Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352587817300360 |